Mahmud Mossa-Basha1, Adam de Havenon2, Kyra J Becker2, Danial K Hallam2, Michael R Levitt2, Wendy A Cohen2, Daniel S Hippe2, Matthew D Alexander2, David L Tirschwell2, Thomas Hatsukami2, Catherine Amlie-Lefond2, Chun Yuan2. 1. From the Departments of Radiology (M.M.-B., D.K.H., W.A.C., D.S.H., C.Y.), Neurology (K.J.B., D.L.T., C.A.-L.), Neurosurgery (M.R.L.), and Surgery (T.H.), University of Washington, Seattle, WA; Department of Neurology, University of Utah, Salt Lake City (A.d.H.); and Department of Radiology, University of California-San Francisco (M.D.A.). mmossab@uw.edu. 2. From the Departments of Radiology (M.M.-B., D.K.H., W.A.C., D.S.H., C.Y.), Neurology (K.J.B., D.L.T., C.A.-L.), Neurosurgery (M.R.L.), and Surgery (T.H.), University of Washington, Seattle, WA; Department of Neurology, University of Utah, Salt Lake City (A.d.H.); and Department of Radiology, University of California-San Francisco (M.D.A.).
Abstract
BACKGROUND AND PURPOSE: Although studies have evaluated the differential imaging of moyamoya disease and atherosclerosis, none have investigated the added value of vessel wall magnetic resonance imaging (MRI). This study evaluates the added diagnostic value of vessel wall MRI in differentiating moyamoya disease, atherosclerotic-moyamoya syndrome (A-MMS), and vasculitic-MMS (V-MMS) with a multicontrast protocol. METHODS: We retrospectively reviewed the carotid artery territories of patients with clinically defined vasculopathies (moyamoya disease, atherosclerosis, and vasculitis) and steno-occlusive intracranial carotid disease. Two neuroradiologists, blinded to clinical data reviewed the luminal imaging of each carotid, evaluating collateral extent and making a presumed diagnosis with diagnostic confidence. After 3 weeks, the 2 readers reviewed the luminal imaging+vessel wall MRI for the presence, pattern and intensity of postcontrast enhancement, T2 signal characteristics, pattern of involvement, and presumed diagnosis and confidence. RESULTS: Ten A-MMS, 3 V-MMS, and 8 moyamoya disease cases with 38 affected carotid segments were included. There was significant improvement in diagnostic accuracy with luminal imaging+vessel wall MRI when compared with luminal imaging (87% versus 32%, P<0.001). The most common vessel wall MRI findings for moyamoya disease were nonenhancing, nonremodeling lesions without T2 heterogeneity; for A-MMS eccentric, remodeling, and T2 heterogeneous lesions with mild/moderate and homogeneous/heterogeneous enhancement; and for V-MMS concentric lesions with homogeneous, moderate enhancement. Inter-reader agreement was moderate to substantial for all vessel wall MRI characteristics (κ=0.46-0.86) and fair for collateral grading (κ=0.35). There was 11% inter-reader agreement for diagnosis on luminal imaging when compared with 82% for luminal imaging+vessel wall MRI (P<0.001). CONCLUSIONS: Vessel wall MRI can significantly improve the differentiation of moyamoya vasculopathies when combined with traditional imaging techniques.
BACKGROUND AND PURPOSE: Although studies have evaluated the differential imaging of moyamoya disease and atherosclerosis, none have investigated the added value of vessel wall magnetic resonance imaging (MRI). This study evaluates the added diagnostic value of vessel wall MRI in differentiating moyamoya disease, atherosclerotic-moyamoya syndrome (A-MMS), and vasculitic-MMS (V-MMS) with a multicontrast protocol. METHODS: We retrospectively reviewed the carotid artery territories of patients with clinically defined vasculopathies (moyamoya disease, atherosclerosis, and vasculitis) and steno-occlusive intracranial carotid disease. Two neuroradiologists, blinded to clinical data reviewed the luminal imaging of each carotid, evaluating collateral extent and making a presumed diagnosis with diagnostic confidence. After 3 weeks, the 2 readers reviewed the luminal imaging+vessel wall MRI for the presence, pattern and intensity of postcontrast enhancement, T2 signal characteristics, pattern of involvement, and presumed diagnosis and confidence. RESULTS: Ten A-MMS, 3 V-MMS, and 8 moyamoya disease cases with 38 affected carotid segments were included. There was significant improvement in diagnostic accuracy with luminal imaging+vessel wall MRI when compared with luminal imaging (87% versus 32%, P<0.001). The most common vessel wall MRI findings for moyamoya disease were nonenhancing, nonremodeling lesions without T2 heterogeneity; for A-MMS eccentric, remodeling, and T2 heterogeneous lesions with mild/moderate and homogeneous/heterogeneous enhancement; and for V-MMS concentric lesions with homogeneous, moderate enhancement. Inter-reader agreement was moderate to substantial for all vessel wall MRI characteristics (κ=0.46-0.86) and fair for collateral grading (κ=0.35). There was 11% inter-reader agreement for diagnosis on luminal imaging when compared with 82% for luminal imaging+vessel wall MRI (P<0.001). CONCLUSIONS: Vessel wall MRI can significantly improve the differentiation of moyamoya vasculopathies when combined with traditional imaging techniques.
Authors: O Togao; F Mihara; T Yoshiura; A Tanaka; T Noguchi; Y Kuwabara; K Kaneko; T Matsushima; H Honda Journal: AJNR Am J Neuroradiol Date: 2006-02 Impact factor: 3.825
Authors: Ye Qiao; Steven R Zeiler; Saeedeh Mirbagheri; Richard Leigh; Victor Urrutia; Robert Wityk; Bruce A Wasserman Journal: Radiology Date: 2014-01-16 Impact factor: 11.105
Authors: Lorelei D Shoemaker; Michael J Clark; Anil Patwardhan; Gemma Chandratillake; Sarah Garcia; Rong Chen; Alexander A Morgan; Nan Leng; Scott Kirk; Richard Chen; Douglas J Cook; Michael Snyder; Gary K Steinberg Journal: G3 (Bethesda) Date: 2015-11-03 Impact factor: 3.542
Authors: Ji Eun Park; Seung Chai Jung; Sang Hun Lee; Ji Young Jeon; Ji Ye Lee; Ho Sung Kim; Choong-Gon Choi; Sang Joon Kim; Deok Hee Lee; Seon-Ok Kim; Sun U Kwon; Dong-Wha Kang; Jong S Kim Journal: Eur Radiol Date: 2017-05-12 Impact factor: 5.315
Authors: Sarah K Lants; Jennifer M Watchmaker; Meher R Juttukonda; Larry T Davis; Manus J Donahue; Matthew R Fusco Journal: World Neurosurg Date: 2017-12-20 Impact factor: 2.104
Authors: J D Schaafsma; S Rawal; J M Coutinho; J Rasheedi; D J Mikulis; C Jaigobin; F L Silver; D M Mandell Journal: AJNR Am J Neuroradiol Date: 2019-09-05 Impact factor: 3.825
Authors: Mahmud Mossa-Basha; Dean K Shibata; Danial K Hallam; Adam de Havenon; Daniel S Hippe; Kyra J Becker; David L Tirschwell; Thomas Hatsukami; Niranjan Balu; Chun Yuan Journal: Stroke Date: 2017-10-13 Impact factor: 7.914
Authors: Jason Brett Hartman; Hiroko Watase; Jie Sun; Daniel S Hippe; Louis Kim; Michael Levitt; Laligam Sekhar; Niranjan Balu; Thomas Hatsukami; Chun Yuan; Mahmud Mossa-Basha Journal: Br J Radiol Date: 2019-01-30 Impact factor: 3.039
Authors: Petrice M Cogswell; Sarah K Lants; L Taylor Davis; Meher R Juttukonda; Matthew R Fusco; Manus J Donahue Journal: Clin Neuroradiol Date: 2019-08-06 Impact factor: 3.649
Authors: A Kathuveetil; P N Sylaja; S Senthilvelan; C Kesavadas; M Banerjee; B Jayanand Sudhir Journal: AJNR Am J Neuroradiol Date: 2020-01-02 Impact factor: 3.825
Authors: Mahmud Mossa-Basha; Hiroko Watase; Jie Sun; Dean K Shibata; Daniel S Hippe; Niranjan Balu; Thomas Hatsukami; Chun Yuan Journal: Br J Radiol Date: 2019-02-26 Impact factor: 3.039